ASMBAssembly Biosciences, Inc.
Is the business good?
Margins widening. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Operating margin has widened over the past few years, the business is getting more profitable per dollar of sales.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is ASMB?
Assembly Biosciences, Inc. keeps −12% of every revenue dollar as operating profit, against −82% for the median Biotechnology name.
Operating margin · Biotechnology median −82% · 12 months to Q2 2026
- Share count, year on year
- +146%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 85%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | −82% |
| FY2021 | −2122% |
| FY2023 | −903% |
| FY2024 | −159% |
| FY2025 | −17% |
Details›
- Operating margin12 months to Q2 2026
- −12%
- Net margin12 months to Q2 2026
- −0.06%
- Free cash flow margin
- −52%
- R&D as % of revenue
- 85%
- Revenue, trailing twelve months
- $75M
- Free cash flow, trailing twelve months
- −$39M
- Net income, trailing twelve months
- −$42K
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Customers and suppliers
Who buys from ASMB and who it buys from, as the companies report it.
- GILDGilead Sciences100%
Share of revenue · FY2025 10-K
None disclosed.
A company has to disclose every customer behind 10% or more of its revenue. Each share comes from the latest annual report of the company that states it and shows on both companies’ pages; ASMB’s own figures are from its FY2025 10-K. Smaller customers and suppliers go unreported.